This CME-certified series of 5 case studies features expert perspectives from internationally renowned thought leaders in Multiple Myeloma. Choose your preferred therapy and see the aggregate, real-time results of your peers’ choices.
How do you plan to use the new data from the Cancer and Leukemia Group B (CALGB) and Intergroup Francophone du Myelome (IFM) on maintenance lenalidomide in the transplant setting?
This activity is supported by an educational grant from
Millennium, The Takeda Oncology Company.
About This Activity
prIME Oncology’s CommunityOpinion is a unique educational forum that engages oncologists by having clinical experts ask prIME Oncology network members their opinion on specific contemporary and controversial topics in oncology.
The CommunityOpinion forum allows participants to respond to, share, and view other members’ answers, as well as pose questions of their own.